Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:GNPX 15 October 2025

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex shares surged 41% after hours on Oct 14, 2025, to $0.36 following new data on its lead cancer therapy. The stock closed regular trading up 30% at $0.25, with volume spiking to 15 million shares. Market cap reached about $11 million. The company’s REQORSA gene therapy is in Phase 2 trials for lung cancer, with new preclinical data set for release at an upcoming oncology conference.
15 October 2025
···

Stock Market Today

  • 3 Worst-Performing Singapore Blue Chips in 2026: Genting Singapore Leads Decline
    March 20, 2026, 8:29 AM EDT. Singapore's stock market faced headwinds in early 2026. Genting Singapore Limited (SGX: G13) emerged as the worst YTD performer among blue chips, with its share price down 8.3% by mid-March. The integrated resort operator's FY2025 net profit plunged 33% year-on-year to S$390.3 million amid a softer gaming recovery and ongoing renovations at Resorts World Sentosa. Gaming segment weakness, intensified competition from Marina Bay Sands, and hotel occupancy challenges weighed on results. Despite a recovering broader gaming market, Genting Singapore's transformation phase and operational disruptions have depressed earnings. The outlook hinges on completion of renovations and stabilizing non-gaming segments. Investors watch for potential turnaround triggers amid income opportunities re-emerging across the Singapore market.
Go toTop